biostudies-literatureUnknown6(1)Patil A<h4>Background</h4>We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).<h4>Methods</h4>This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome.<h4>Results</h4>COVID-19 occurred in 314 (3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129, 219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. GlucocorticoiBMC rheumatology32https://www.ebi.ac.uk/biostudies/studies/S-EPMC9192133biostudies-literatureA prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases.PMC9192133Chandrashekara SSangeetha KNSrinivasa CRao VKNagaraj SChanakya KDharmanand BGPatil ADaware MHaridas VKumar SPinto BDharmapalaiah CJanardana RJois RSinghai SSubramanian RJain VShenoy PSingh YPShobha VfalseA prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases.<h4>Background</h4>We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).<h4>Methods</h4>This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome.<h4>Results</h4>COVID-19 occurred in 314 (3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129, 219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. Glucocorticoi2022-01-01T00:00:00Z2022 Jun2025-04-04T09:27:28.694Z2024-10-19T13:26:33.41ZS-EPMC91921333569818210.1186/s41927-022-00264-0